Double-Blind, Randomized Study of the Efficacy and Safety of Oral Pharmacokinetically Enhanced Amoxicillin-Clavulanate (2,000/125 Milligrams) versus Those of Amoxicillin-Clavulanate (875/125 Milligrams), Both Given Twice Daily for 7 Days, in Treatment of Bacterial Community-Acquired Pneumonia in Adults

This randomized, double-blind, noninferiority trial was designed to demonstrate that pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 mg) was at least as effective clinically as amoxicillin-clavulanate 875/125 mg, both given twice daily for 7 days, in the treatment of community-acquir...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: File, T. M., Lode, H., Kurz, H., Kozak, R., Xie, H., Berkowitz, E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2004
Gaiak:
Clinical Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC514768/
https://ncbi.nlm.nih.gov/pubmed/15328092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.9.3323-3331.2004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak